Breast Cancer Update
Dr. Neil Love
Featuring one-on-one interviews conducted by Dr Neil Love, this series bridges the gap between research and patient care by providing medical oncologists, hematologists and hematology-oncology fellows ongoing access to the perspectives and opinions of national and international breast cancer clinical investigators.
Episodes
Mentioned books
Dec 16, 2024 • 12min
5-Minute Journal Club Issue 2 with Dr Seth Wander: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast Cancer
Dr Seth Wander from Massachusetts General Hospital in Boston discusses recent developments with oral SERDs in the management of ER-positive metastatic breast cancer.
Dec 5, 2024 • 60min
Exploring the Current Management Paradigm for Patients with Metastatic Triple-Negative Breast Cancer
Dr Priyanka Sharma from The University of Kansas Cancer Center in Westwood and Dr Sara M Tolaney from Dana-Farber Cancer Center in Boston discuss recent updates on available and novel treatment strategies for metastatic triple-negative breast cancer.
Nov 26, 2024 • 11min
5-Minute Journal Club Issue 1 with Dr Seth Wander: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast Cancer
Dr Seth Wander from Massachusetts General Hospital in Boston discusses recent developments with oral selective estrogen receptor degraders for ER-positive metastatic breast cancer.
Nov 19, 2024 • 57min
Optimizing Therapy for Patients with Hormone Receptor-Positive Metastatic Breast Cancer Harboring PI3K/AKT/PTEN Pathway Abnormalities
Dr Komal Jhaveri from Memorial Sloan Kettering Cancer Center in New York, New York, and Dr Hope S Rugo from the UCSF Helen Diller Family Comprehensive Cancer Center discuss treatment decision-making for HR-positive metastatic breast cancer in patients who harbor PI3K/AKT/PTEN pathway mutations.
Nov 16, 2024 • 1h 4min
Data + Perspectives: Clinical Investigators Explore the Application of Recent Datasets in Current Oncology Care — Breast Cancer
Specialist clinical investigators share their perspectives on the evolving therapeutic landscape for patients with HR-positive breast cancer.
Nov 1, 2024 • 59min
Improving Outcomes with First-Line Endocrine-Based Therapy for Patients with HR-Positive, HER2-Negative Metastatic Breast Cancer
Prof. Francois-Clement Bidard from Institut Curie in Paris and Dr. Kevin Kalinsky from Winship Cancer Institute dive into enhancing treatments for HR-positive, HER2-negative metastatic breast cancer. They explore the role of CDK inhibitors in older patients and the impact of ESR1 mutations on treatment resistance. The discussion highlights the evolution of clinical trials, personalized therapies, and innovative strategies aimed at improving long-term patient outcomes. Together, they emphasize the importance of patient involvement and genetic insights in shaping treatment decisions.
Oct 25, 2024 • 46min
Oncology Today with Dr Neil Love: Potential Role of PROTAC ER Degraders in Therapy for HR-Positive Metastatic Breast Cancer
Dr Erika Hamilton from Sarah Cannon Research Institute in Nashville discusses emerging evidence with proteolysis-targeting chimera estrogen receptor degraders for HR-positive metastatic breast cancer.
Oct 18, 2024 • 59min
Practical Perspectives: Optimizing Diagnosis and Treatment for Patients with Desmoid Tumors
Dr Thierry Alcindor from Dana-Farber Cancer Institute in Boston, Massachusetts, and Dr Mrinal Gounder from Memorial Sloan Kettering Cancer Center in New York, New York, summarize the treatment landscape for desmoid tumors and review novel options for targeted therapy.
Sep 25, 2024 • 50min
Oncology Today with Dr Neil Love: Optimizing the Management of Metastatic BRCA-Negative, Triple-Negative Breast Cancer
Dr. Tiffany Traina, a medical oncologist from Memorial Sloan Kettering Cancer Center, dives deep into the management of metastatic BRCA-negative, triple-negative breast cancer. She discusses personalized treatment strategies, emphasizing chemotherapy combined with pembrolizumab for PD-1 positive patients. The conversation also highlights the importance of biopsies and emerging therapies like enzalutamide and antibody-drug conjugates. Additionally, she addresses the complexities of treating elderly patients and navigating toxicity, all while exploring the latest advancements in treatment options.
Sep 6, 2024 • 1h 3min
Inside the Issue: Integrating Antibody-Drug Conjugates into the Management of HR-Positive and Triple-Negative Metastatic Breast Cancer
Prof Peter Schmid from the Barts Cancer Institute in London, United Kingdom, and Dr Sara Tolaney from the Dana-Farber Cancer Institute in Boston, Massachusetts, review clinical trials investigating the role of antibody-drug conjugate-mediated therapies in the treatment of metastatic breast cancer.
